A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Sichuan Cancer Hospital and Research Institute
University of Michigan Rogel Cancer Center
Shantou University Medical College
Odense University Hospital
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Janssen Research & Development, LLC
GOG Foundation
Amgen
OHSU Knight Cancer Institute
University of Chicago
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
University of Southern California
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.